|
1
|
Hartgrink HH, Jansen EP, van Grieken NC
and van de Velde CJ: Gastric cancer. Lancet. 374:477–490. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kanda M, Kobayashi D, Tanaka C, Iwata N,
Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Nomoto S, et
al: Adverse prognostic impact of perioperative allogeneic
transfusion on patients with stage II/III gastric cancer. Gastric
Cancer. 19:255–263. 2016. View Article : Google Scholar
|
|
3
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Leung WK, Wu MS, Kakugawa Y, Kim JJ, Yeoh
KG, Goh KL, Wu KC, Wu DC, Sollano J, Kachintorn U, et al; Asia
Pacific Working Group on Gastric Cancer. Screening for gastric
cancer in Asia: Current evidence and practice. Lancet Oncol.
9:279–287. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kanda M, Mizuno A, Fujii T, Shimoyama Y,
Yamada S, Tanaka C, Kobayashi D, Koike M, Iwata N, Niwa Y, et al:
Tumor infiltrative pattern predicts sites of recurrence after
curative gastrectomy for stages 2 and 3 gastric cancer. Ann Surg
Oncol. 23:1934–1940. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Paoletti X, Oba K, Burzykowski T, Michiels
S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M,
et al; GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research
International Collaboration) Group. Benefit of adjuvant
chemotherapy for resectable gastric cancer: A meta-analysis. JAMA.
303:1729–1737. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
McLean MH and El-Omar EM: Genetics of
gastric cancer. Nat Rev Gastroenterol Hepatol. 11:664–674. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kanda M, Nomoto S, Oya H, Takami H,
Shimizu D, Hibino S, Hashimoto R, Kobayashi D, Tanaka C, Yamada S,
et al: The expression of melanoma-associated antigen D2 both in
surgically resected and serum samples serves as clinically relevant
biomarker of gastric cancer progression. Ann Surg Oncol. 23(Suppl
2): S214–S221. 2016. View Article : Google Scholar
|
|
9
|
Jang BG and Kim WH: Molecular pathology of
gastric carcinoma. Pathobiology. 78:302–310. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Resende C, Thiel A, Machado JC and
Ristimäki A: Gastric cancer: Basic aspects. Helicobacter. 16(Suppl
1): 38–44. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kanda M, Shimizu D, Tanaka H, Shibata M,
Iwata N, Hayashi M, Kobayashi D, Tanaka C, Yamada S, Fujii T, et
al: Metastatic pathway-specific transcriptome analysis identifies
MFSD4 as a putative tumor suppressor and biomarker for hepatic
metastasis in patients with gastric cancer. Oncotarget.
7:13667–13679. 2016.PubMed/NCBI
|
|
12
|
Tanaka H, Hoshikawa Y, Oh-hara T, Koike S,
Naito M, Noda T, Arai H, Tsuruo T and Fujita N: PRMT5, a novel
TRAIL receptor-binding protein, inhibits TRAIL-induced apoptosis
via nuclear factor-kappaB activation. Mol Cancer Res. 7:557–569.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bao X, Zhao S, Liu T, Liu Y, Liu Y and
Yang X: Overexpression of PRMT5 promotes tumor cell growth and is
associated with poor disease prognosis in epithelial ovarian
cancer. J Histochem Cytochem. 61:206–217. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nicholas C, Yang J, Peters SB, Bill MA,
Baiocchi RA, Yan F, Sïf S, Tae S, Gaudio E, Wu X, et al: PRMT5 is
upregulated in malignant and metastatic melanoma and regulates
expression of MITF and p27Kip1. PLoS One. 8:e747102013.
View Article : Google Scholar
|
|
15
|
Aggarwal P, Vaites LP, Kim JK, Mellert H,
Gurung B, Nakagawa H, Herlyn M, Hua X, Rustgi AK, McMahon SB, et
al: Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and
triggers neoplastic growth via activation of the PRMT5
methyl-transferase. Cancer Cell. 18:329–340. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tee WW, Pardo M, Theunissen TW, Yu L,
Choudhary JS, Hajkova P and Surani MA: Prmt5 is essential for early
mouse development and acts in the cytoplasm to maintain ES cell
pluri-potency. Genes Dev. 24:2772–2777. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Han X, Li R, Zhang W, Yang X, Wheeler CG,
Friedman GK, Province P, Ding Q, You Z, Fathallah-Shaykh HM, et al:
Expression of PRMT5 correlates with malignant grade in gliomas and
plays a pivotal role in tumor growth in vitro. J Neurooncol.
118:61–72. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ibrahim R, Matsubara D, Osman W, Morikawa
T, Goto A, Morita S, Ishikawa S, Aburatani H, Takai D, Nakajima J,
et al: Expression of PRMT5 in lung adenocarcinoma and its
significance in epithelial-mesenchymal transition. Hum Pathol.
45:1397–1405. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Y, Chitnis N, Nakagawa H, Kita Y,
Natsugoe S, Yang Y, Li Z, Wasik M, Klein-Szanto AJ, Rustgi AK, et
al: PRMT5 is required for lymphomagenesis triggered by multiple
oncogenic drivers. Cancer Discov. 5:288–303. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Stopa N, Krebs JE and Shechter D: The
PRMT5 arginine methyl-transferase: Many roles in development,
cancer and beyond. Cell Mol Life Sci. 72:2041–2059. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kanda M, Shimizu D, Nomoto S, Takami H,
Hibino S, Oya H, Hashimoto R, Suenaga M, Inokawa Y, Kobayashi D, et
al: Prognostic impact of expression and methylation status of
DENN/MADD domain-containing protein 2D in gastric cancer. Gastric
Cancer. 18:288–296. 2015. View Article : Google Scholar
|
|
22
|
Kanda M, Kodera Y and Sakamoto J: Updated
evidence on adjuvant treatments for gastric cancer. Expert Rev
Gastroenterol Hepatol. 9:1549–1560. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sakuramoto S, Sasako M, Yamaguchi T,
Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi
Y, Imamura H, et al; ACTS-GC Group. Adjuvant chemotherapy for
gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med.
357:1810–1820. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kanda M, Murotani K, Kobayashi D, Tanaka
C, Yamada S, Fujii T, Nakayama G, Sugimoto H, Koike M, Fujiwara M,
et al: Postoperative adjuvant chemotherapy with S-1 alters
recurrence patterns and prognostic factors among patients with
stage II/III gastric cancer: A propensity score matching analysis.
Surgery. 158:1573–1580. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kanda M, Oya H, Nomoto S, Takami H,
Shimizu D, Hashimoto R, Sueoka S, Kobayashi D, Tanaka C, Yamada S,
et al: Diversity of clinical implication of B-cell translocation
gene 1 expression by histopathologic and anatomic subtypes of
gastric cancer. Dig Dis Sci. 60:1256–1264. 2015. View Article : Google Scholar
|
|
26
|
Kanda M, Shimizu D, Fujii T, Sueoka S,
Tanaka Y, Ezaka K, Takami H, Tanaka H, Hashimoto R, Iwata N, et al:
Function and diagnostic value of Anosmin-1 in gastric cancer
progression. Int J Cancer. 138:721–730. 2016. View Article : Google Scholar
|
|
27
|
Oya H, Kanda M, Sugimoto H, Shimizu D,
Takami H, Hibino S, Hashimoto R, Okamura Y, Yamada S, Fujii T, et
al: Dihydropyrimidinase-like 3 is a putative hepatocellular
carcinoma tumor suppressor. J Gastroenterol. 50:590–600. 2015.
View Article : Google Scholar
|
|
28
|
Gervasi M, Bianchi-Smiraglia A, Cummings
M, Zheng Q, Wang D, Liu S and Bakin AV: JunB contributes to Id2
repression and the epithelial-mesenchymal transition in response to
transforming growth factor-β. J Cell Biol. 196:589–603. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yan F, Alinari L, Lustberg ME, Martin LK,
Cordero-Nieves HM, Banasavadi-Siddegowda Y, Virk S, Barnholtz-Sloan
J, Bell EH, Wojton J, et al: Genetic validation of the protein
arginine methyltransferase PRMT5 as a candidate therapeutic target
in glioblastoma. Cancer Res. 74:1752–1765. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Smil D, Eram MS, Li F, Kennedy S, Szewczyk
MM, Brown PJ, Barsyte-Lovejoy D, Arrowsmith CH, Vedadi M and
Schapira M: Discovery of a dual PRMT5-PRMT7 inhibitor. ACS Med Chem
Lett. 6:408–412. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hu M, Xia M, Chen X, Lin Z, Xu Y, Ma Y and
Su L: MicroRNA-141 regulates Smad interacting protein 1 (SIP1) and
inhibits migration and invasion of colorectal cancer cells. Dig Dis
Sci. 55:2365–2372. 2010. View Article : Google Scholar
|
|
32
|
Okugawa Y, Inoue Y, Tanaka K, Kawamura M,
Saigusa S, Toiyama Y, Ohi M, Uchida K, Mohri Y and Kusunoki M: Smad
interacting protein 1 (SIP1) is associated with peritoneal
carcinomatosis in intestinal type gastric cancer. Clin Exp
Metastasis. 30:417–429. 2013. View Article : Google Scholar
|
|
33
|
Karihtala P, Auvinen P, Kauppila S,
Haapasaari KM, Jukkola-Vuorinen A and Soini Y: Vimentin, zeb1 and
Sip1 are up-regulated in triple-negative and basal-like breast
cancers: Association with an aggressive tumour phenotype. Breast
Cancer Res Treat. 138:81–90. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Thakur R, Trivedi R, Rastogi N, Singh M
and Mishra DP: Inhibition of STAT3, FAK and Src mediated signaling
reduces cancer stem cell load, tumorigenic potential and metastasis
in breast cancer. Sci Rep. 5:101942015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang T, Yuan J, Zhang J, Tian R, Ji W,
Zhou Y, Yang Y, Song W, Zhang F and Niu R: Anxa2 binds to STAT3 and
promotes epithelial to mesenchymal transition in breast cancer
cells. Oncotarget. 6:30975–30992. 2015.PubMed/NCBI
|
|
36
|
Kim BR, Oh SC, Lee DH, Kim JL, Lee SY,
Kang MH, Lee SI, Kang S, Joung SY and Min BW: BMP-2 induces
motility and invasiveness by promoting colon cancer stemness
through STAT3 activation. Tumour Biol. 36:9475–9486. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Taylor MA, Davuluri G, Parvani JG,
Schiemann BJ, Wendt MK, Plow EF, Schiemann WP and Sossey-Alaoui K:
Upregulated WAVE3 expression is essential for TGF-β-mediated EMT
and metastasis of triple-negative breast cancer cells. Breast
Cancer Res Treat. 142:341–353. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gao J, Zhu Y, Nilsson M and Sundfeldt K:
TGF-β isoforms induce EMT independent migration of ovarian cancer
cells. Cancer Cell Int. 14:722014. View Article : Google Scholar
|
|
39
|
Kanda M, Nomoto S, Oya H, Shimizu D,
Takami H, Hibino S, Hashimoto R, Kobayashi D, Tanaka C, Yamada S,
et al: Dihydropyrimidinase-like 3 facilitates malignant behavior of
gastric cancer. J Exp Clin Cancer Res. 33:662014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yoo CH, Noh SH, Shin DW, Choi SH and Min
JS: Recurrence following curative resection for gastric carcinoma.
Br J Surg. 87:236–242. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Shen L, Shan YS, Hu HM, Price TJ, Sirohi
B, Yeh KH, Yang YH, Sano T, Yang HK, Zhang X, et al: Management of
gastric cancer in Asia: Resource-stratified guidelines. Lancet
Oncol. 14:e535–e547. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kanda M, Nomoto S, Oya H, Hashimoto R,
Takami H, Shimizu D, Sonohara F, Kobayashi D, Tanaka C, Yamada S,
et al: Decreased expression of prenyl diphosphate synthase subunit
2 correlates with reduced survival of patients with gastric cancer.
J Exp Clin Cancer Res. 33:882014. View Article : Google Scholar : PubMed/NCBI
|
